Oncogenic anaplastic lymphoma kinase ( ALK) mutation in neuroblastomas and other pediatric tumors

Neuroblastoma (NB) is one of the most common malignant pediatric tumors that show aggressive behavior. Most advanced-stage NBs have proven refractory to many treatment modalities, and a fundamental alternative therapy, such as inhibition of biological pathways, is now being explored. Anaplastic lymp...

Full description

Saved in:
Bibliographic Details
Published in:Pathology, research and practice research and practice, 2011-10, Vol.207 (10), p.634-639
Main Authors: Kwon, Mi Jung, Choi, Yoon-La, Sung, Ki Woong, Kang, So Young, Park, Sang Mo, Choi, Song-Yi, Kim, Jung-Sun, Suh, Yeon-Lim
Format: Article
Language:English
Subjects:
Adolescent
Anaplastic lymphoma kinase
Base Sequence
Child
Child, Preschool
Disease-Free Survival
DNA Mutational Analysis
Female
Humans
Infant
Infant, Newborn
Korea
Male
Mutation
Neoplasm Staging
Neuroblastoma
Neuroblastoma - genetics
Neuroblastoma - mortality
Polymerase Chain Reaction
Receptor Protein-Tyrosine Kinases - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neuroblastoma (NB) is one of the most common malignant pediatric tumors that show aggressive behavior. Most advanced-stage NBs have proven refractory to many treatment modalities, and a fundamental alternative therapy, such as inhibition of biological pathways, is now being explored. Anaplastic lymphoma kinase ( ALK) has recently been identified as an activation mutation in familial or high-risk sporadic NBs. We examined the prevalence of the ALK mutation in 54 NB cases (23 pre-treatment cases and 31 cases for which specimens were available before and after treatment) and the presence of the ALK mutation in various pediatric tumors. We detected the ALK mutation (F1174C and R1275Q) in 2 (3.7%) of the 54 NB specimens. Both cases showed poorly differentiated and advanced-stage NBs. No ALK mutations were detected in other pediatric tumors. The frequency of the ALK mutation was somewhat lower than that expected in Korean patients with NBs. The mutation detected in the present study was one of the hotspot mutations, including positions of F1174 and R1275 reported previously. The results of the present study suggest the possibility of potential roles of ALK inhibitors in the therapeutics of a small population of neuroblastoma carrying mutated ALK kinases.
ISSN:0344-0338
1618-0631
DOI:10.1016/j.prp.2011.07.011